Metastatic Malignant Neoplasm clinical trials
12 active trials name this condition. Describe your situation to see which ones look like a fit.
By location
- Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
- Comparison of Whole Body DWI to FDG PET
- Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
- Prospective Validation of a Points Score System Predicting 30-day Survival
- Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
- Detection of Genetic Markers of Lung Cancer
- IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
- Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis
- Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
- Comprehensive Outcomes for After Cancer Health
- Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
- Defining the Ablative Dose for Y-90 TARE
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Metastatic Malignant Neoplasm” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.